{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:00Z","timestamp":1792788720720,"version":"4.5.0"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["58233"],"award-info":[{"award-number":["58233"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["GZ-2015-11485"],"award-info":[{"award-number":["GZ-2015-11485"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hong Kong Special Administrative Region Government Health and Medical Research Fund","award":["05160976"],"award-info":[{"award-number":["05160976"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0239675","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T18:04:20Z","timestamp":1601316260000},"page":"e0239675","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy"],"prefix":"10.1371","volume":"15","author":[{"given":"Chandu","family":"Sadasivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie T. Y.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bun","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K. H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C. L.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey K. T.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel M. B.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsz-Ngai","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K. H.","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Y. S.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Kin","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ian","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manohara","family":"Senaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Brass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9154-9028","authenticated-orcid":true,"given":"Gavin Y.","family":"Oudit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex P. W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"issue":"6","key":"pone.0239675.ref001","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","article-title":"Narrative Review: Fabry Disease","volume":"146","author":"JTR Clarke","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"pone.0239675.ref002","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The Molecular Defect Leading to Fabry Disease: Structure of Human \u03b1-Galactosidase","volume":"337","author":"SC Garman","year":"2004","journal-title":"Journal of Molecular Biology"},{"issue":"33","key":"pone.0239675.ref003","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.2174\/13816128113199990352","article-title":"Anderson-Fabry Disease: A Multiorgan Disease.","volume":"19","author":"T Antonino","year":"2013","journal-title":"Current Pharmaceutical Design"},{"issue":"7","key":"pone.0239675.ref004","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cjca.2017.04.015","article-title":"Clinical Features, Diagnosis, and Management of Patients With Anderson-Fabry Cardiomyopathy","volume":"33","author":"H Yogasundaram","year":"2017","journal-title":"Can J Cardiol"},{"issue":"2","key":"pone.0239675.ref005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10741-014-9452-9","article-title":"Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment","volume":"20","author":"BN Putko","year":"2015","journal-title":"Heart Failure Reviews"},{"issue":"3","key":"pone.0239675.ref006","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson\u2013Fabry disease related cardiomyopathy.","volume":"130","author":"C Kampmann","year":"2008","journal-title":"International Journal of Cardiology."},{"issue":"11","key":"pone.0239675.ref007","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry","volume":"11","author":"S Waldek","year":"2009","journal-title":"Genetics in Medicine"},{"issue":"11","key":"pone.0239675.ref008","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"KD MacDermot","year":"2001","journal-title":"Journal of Medical Genetics"},{"issue":"11","key":"pone.0239675.ref009","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"KD MacDermot","year":"2001","journal-title":"Journal of Medical Genetics"},{"issue":"1","key":"pone.0239675.ref010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and Efficacy of Recombinant Human \u03b1-Galactosidase A Replacement Therapy in Fabry's Disease.","volume":"345","author":"CM Eng","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"pone.0239675.ref011","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy","volume":"119","author":"F Weidemann","year":"2009","journal-title":"Circulation"},{"issue":"4","key":"pone.0239675.ref012","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ymgme.2009.11.001","article-title":"Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative","volume":"99","author":"S Sirrs","year":"2010","journal-title":"Molecular Genetics and Metabolism"},{"issue":"12","key":"pone.0239675.ref013","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00392-002-0870-7","article-title":"Fabry disease in patients with hypertrophic cardiomyopathy (HCM).","volume":"91","author":"G Beer","year":"2002","journal-title":"Zeitschrift f\u00fcr Kardiologie"},{"key":"pone.0239675.ref014","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: a key feature of Fabry disease with potential therapeutic implications.","volume":"8","author":"F Weidemann","year":"2013","journal-title":"Orphanet J Rare Dis."},{"issue":"2","key":"pone.0239675.ref015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase \u03b2 improves cardiac involvement in Fabry's disease","volume":"66","author":"L Spinelli","year":"2004","journal-title":"Clinical Genetics"},{"issue":"11","key":"pone.0239675.ref016","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of Cardiac Function During Enzyme Replacement Therapy in Patients With Fabry Disease","volume":"108","author":"F Weidemann","year":"2003","journal-title":"Circulation"},{"issue":"6","key":"pone.0239675.ref017","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"DP Germain","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0239675.ref018","doi-asserted-by":"crossref","first-page":"e000058","DOI":"10.1161\/HCG.0000000000000058","article-title":"Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association. Circulation","volume":"12","author":"S Cresci","year":"2019","journal-title":"Genomic and Precision Medicine"},{"issue":"1","key":"pone.0239675.ref019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"RM Lang","year":"2015","journal-title":"Journal of the American Society of Echocardiography"},{"issue":"4","key":"pone.0239675.ref020","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.echo.2017.02.009","article-title":"Recommendations on the Echocardiographic Assessment of Aortic Valve Stenosis: A Focused Update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"30","author":"H Baumgartner","year":"2017","journal-title":"Journal of the American Society of Echocardiography"},{"issue":"1","key":"pone.0239675.ref021","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2007.05.082","article-title":"Screening for pharmacological chaperones in Fabry disease","volume":"359","author":"S-H Shin","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"pone.0239675.ref022","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM200107053450104","article-title":"Improvement in Cardiac Function in the Cardiac Variant of Fabry's Disease with Galactose-Infusion Therapy.","volume":"345","author":"A Frustaci","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"pone.0239675.ref023","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1159\/000494678","article-title":"Results of Fabry Disease Screening in Male Pre-End Stage Renal Disease Patients with Unknown Etiology Found Through the Platform of a Chronic Kidney Disease Education Program in a Northern Taiwan Medical Center.","volume":"43","author":"CJ Lin","year":"2018","journal-title":"Kidney and Blood Pressure Research"},{"key":"pone.0239675.ref024","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease.","volume":"5","author":"DP Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"pone.0239675.ref025","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.116.001639","article-title":"Fabry Disease in Families With Hypertrophic Cardiomyopathy: Clinical Manifestations in the Classic and Later-Onset Phenotypes.","volume":"10","author":"B Adalsteinsdottir","year":"2017","journal-title":"Circ Cardiovasc Genet."},{"issue":"10","key":"pone.0239675.ref026","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jacc.2016.05.090","article-title":"Genetic Screening of Anderson-Fabry Disease in Probands Referred From Multispecialty Clinics","volume":"68","author":"V Favalli","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"pone.0239675.ref027","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1517\/17530059.2013.846322","article-title":"Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature?","volume":"7","author":"AS Thomas","year":"2013","journal-title":"Expert Opinion on Medical Diagnostics"},{"issue":"1","key":"pone.0239675.ref028","doi-asserted-by":"crossref","first-page":"e12914","DOI":"10.1111\/ijcp.12914","article-title":"Time delays in the diagnosis and treatment of Fabry disease","volume":"71","author":"R Reisin","year":"2017","journal-title":"International Journal of Clinical Practice"},{"issue":"1","key":"pone.0239675.ref029","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0009-8981(01)00478-8","article-title":"Fabry disease: enzymatic diagnosis in dried blood spots on filter paper","volume":"308","author":"NA Chamoles","year":"2001","journal-title":"Clinica Chimica Acta"},{"issue":"12","key":"pone.0239675.ref030","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ejmg.2015.10.014","article-title":"Enzymatic diagnosis of Fabry disease using a fluorometric assay on dried blood spots: An alternative methodology","volume":"58","author":"E Caudron","year":"2015","journal-title":"European Journal of Medical Genetics"},{"issue":"4","key":"pone.0239675.ref031","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults","volume":"92","author":"BJ Maron","year":"1995","journal-title":"Circulation"},{"issue":"12","key":"pone.0239675.ref032","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic Cardiomyopathy","volume":"105","author":"B Sachdev","year":"2002","journal-title":"Circulation"},{"issue":"9","key":"pone.0239675.ref033","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","article-title":"Prevalence of Fabry Disease in Female Patients With Late-Onset Hypertrophic Cardiomyopathy","volume":"110","author":"C Chimenti","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"pone.0239675.ref034","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An Atypical Variant of Fabry's Disease in Men with Left Ventricular Hypertrophy.","volume":"333","author":"S Nakao","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"pone.0239675.ref035","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson\u2013Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson\u2013Fabry Disease Survey","volume":"97","author":"P Elliott","year":"2011","journal-title":"Heart"},{"issue":"25","key":"pone.0239675.ref036","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"L Monserrat","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"pone.0239675.ref037","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jjcc.2016.05.014","article-title":"Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy","volume":"69","author":"T Kubo","year":"2017","journal-title":"Journal of Cardiology"},{"issue":"5","key":"pone.0239675.ref038","first-page":"450","article-title":"High Incidence of the Cardiac Variant of Fabry Disease Revealed by Newborn Screening in the Taiwan Chinese Population.","volume":"2","author":"H-Y Lin","year":"2009","journal-title":"Circulation: Cardiovascular Genetics."},{"issue":"52","key":"pone.0239675.ref039","doi-asserted-by":"crossref","first-page":"87161","DOI":"10.18632\/oncotarget.13552","article-title":"Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation.","volume":"7","author":"Y Chien","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"pone.0239675.ref040","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2119\/molmed.2012.00002","article-title":"Fabry disease: incidence of the common later-onset \u03b1-galactosidase A IVS4+919G\u2192A mutation in Taiwanese newborns-superiority of DNA-based to enzyme-based newborn screening for common mutations","volume":"18","author":"Y-H Chien","year":"2012","journal-title":"Mol Med"},{"issue":"7","key":"pone.0239675.ref041","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s10038-020-0745-7","article-title":"The Fabry disease-causing mutation, GLA IVS4+919G>A, originated in Mainland China more than 800 years ago","volume":"65","author":"K-H Liang","journal-title":"Journal of Human Genetics"},{"issue":"01","key":"pone.0239675.ref042","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"G Ruiz-Irastorza","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"20","key":"pone.0239675.ref043","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of Rheumatoid Arthritis with Methotrexate Alone, Sulfasalazine and Hydroxychloroquine, or a Combination of All Three Medications","volume":"334","author":"JR O'Dell","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"pone.0239675.ref044","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0049-0172(78)90033-1","article-title":"Antimalarials in the management of discoid and systemic lupus erythematosus","volume":"8","author":"EL Dubois","year":"1978","journal-title":"Semin Arthritis Rheum"},{"key":"pone.0239675.ref045","article-title":"Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).","author":"NJ Mercuro","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"3","key":"pone.0239675.ref046","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ehf2.12276","article-title":"Chloroquine-induced cardiomyopathy: a reversible cause of heart failure","volume":"5","author":"H Yogasundaram","year":"2018","journal-title":"ESC Heart Failure"},{"issue":"1","key":"pone.0239675.ref047","doi-asserted-by":"crossref","first-page":"E70","DOI":"10.21037\/jtd.2017.12.66","article-title":"Hydroxychloroquine-induced cardiomyopathy and heart failure in twins","volume":"10","author":"H Zhao","year":"2017","journal-title":"Journal of Thoracic Disease"},{"issue":"12","key":"pone.0239675.ref048","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.cjca.2014.08.016","article-title":"Hydroxychloroquine-Induced Cardiomyopathy: Case Report, Pathophysiology, Diagnosis, and Treatment","volume":"30","author":"H Yogasundaram","year":"2014","journal-title":"Canadian Journal of Cardiology"},{"issue":"4","key":"pone.0239675.ref049","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3899\/jrheum.180124","article-title":"Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?","volume":"46","author":"K Tselios","year":"2019","journal-title":"J Rheumatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0239675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T18:30:32Z","timestamp":1668969032000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0239675"}},"subtitle":[],"editor":[{"given":"Antonio","family":"Cannat\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0239675","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]}}}